Introduction {#section1-1756286418759189}
============

The central European MS Expert Board was founded in 2007 with the aim of improving the management and (availability of) care of multiple sclerosis (MS) patients in the central European area. The original member countries include Austria, the Czech Republic, Hungary, Poland, Slovakia, and Slovenia. Renowned MS experts from these countries have been convening for periodical meetings to share practical aspects including local treatment algorithms, educational requirements, data gaps, and support for local argumentation/negotiation gaps with health authorities.

It was generally agreed that there is a need to improve care of MS patients in the light of increasing complexity of MS therapy and heightened demands in excellence at MS centers. Identifying local needs, even if potential measures appear visionary at the time of their discussion, has become an important part of the board's work. The expert board is being perceived as a solution-oriented forum guided by pragmatism and transparency.

This paper summarizes the content discussed at the most recent board meeting held on January 21, 2017, in Vienna, Austria. Lectures and debates focused on gaps in daily MS management in the respective countries and prioritized problem-solving approaches.

Burden of disease in Europe {#section2-1756286418759189}
===========================

Similarities and differences with respect to the burden of MS across Europe have been assessed by the observational, cross-sectional, retrospective MS Cost Of Illness (MS COI) Study that contains data from 16,808 patients in 16 countries (Austria, Belgium, Czech Republic, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom).^[@bibr1-1756286418759189]^ MS COI is a patient survey based on paper and online questionnaires that were distributed by 18 patient advocacy groups. It thus provides a snapshot of the experience of the responding patients, rather than representing a prevalence sample. The findings can therefore be expected to bear a certain selection bias; however, generally speaking, they are in keeping with other large datasets of a similar nature.^[@bibr2-1756286418759189],[@bibr3-1756286418759189]^ Individual papers on the MS COI results will be published for each country this year.

The survey population shows the full range of disease severity according to the Expanded Disability Status Scale (EDSS). Mean EDSS scores for the individual countries ranged from 2.9 (Russia) to 5.5 (United Kingdom). However, comparisons across countries are difficult due to inherent variations with regard to healthcare systems, medical traditions, purchasing power and other parameters. Also, as this is a cross-sectional study, causal inference is not possible.

A consistent finding across Europe was the steep decrease in quality of life as EDSS increases ([Figure 1](#fig1-1756286418759189){ref-type="fig"}), which illustrates the need to avert disease progression. At the same time, the total costs increased dramatically. According to the analysis of cost structure, expenses for disease-modifying drugs (DMDs) amounted to 27% in the total study population ([Figure 2](#fig2-1756286418759189){ref-type="fig"}). However, the largest component constituted indirect costs relating to factors such as production losses and caregiver burden. Due to differences in mechanisms of care delivery, types of patients and levels of severity, cost structure varied considerably across countries. This also applied to types of hospitalization (percentages of inpatient stays, day admissions, use of rehabilitation and nursing home services) and types of healthcare professionals that MS patients tend to consult. Here, the proportions of consultations with neurologists, MS nurses, general practitioners and physiotherapists differed conspicuously across countries. On average, 22.5% of patients reported MRI brain examinations within the previous 3 months.

![Effect of disease progression in multiple sclerosis patients on quality of life (left) and financial burden (right) in 16 European countries.\
Source: Kobelt *et al.*^[@bibr1-1756286418759189]^\
EDSS, Expanded Disability Status Scale.](10.1177_1756286418759189-fig1){#fig1-1756286418759189}

![Cost structure in the Multiple Sclerosis Cost of Illness (MS COI) study in the total study population (*n* = 16,808).\
Kobelt *et al.*^[@bibr1-1756286418759189]^\
DMDs, disease-modifying drugs.](10.1177_1756286418759189-fig2){#fig2-1756286418759189}

The mean cost of relapses occurring during a 3-month reporting period was estimated at EUR 2188 (adjusted for purchasing power); wide variations were seen in these costs, with country means ranging from EUR 632 to EUR 4569. Approximately 40% of the total working-age population with MS were not working because of their disease at the time of the survey. This is a substantial proportion. Therefore, keeping the patients in the workforce and maximizing their ability to contribute productively to the economy should be an important treatment goal. Moreover, this aspect of the burden of MS is an essential factor to take into consideration when demonstrating the cost effectiveness of disease-modifying therapies.

Although pertinent data delineating the spectrum of MS treatment in European countries have been generated through this survey, it can be expected that national health authorities show little inclination to consider them in their daily proceedings, as their interest in diminishing indirect cost savings is generally limited. This might even be true for health insurances that only cover expenses for medical conditions and accidents, but not for retirement, which means that early retirement of an MS patient relieves them of their duties towards this patient. Therefore, there is agreement that it is advisable to form local partnerships with other authorities such as The Chamber of Labour in Austria that represents the interests of employees, with the aim of leveraging the importance of these epidemiological data. As a rule, providing local authorities with data on the burden of disease is preferable to waiting for them to present the MS community with data of their own.

Access to treatment {#section3-1756286418759189}
===================

MS patients in all countries should have fair and equal access to the right treatments at the right time. However, this is not the case due to a number of reasons ([Table 1](#table1-1756286418759189){ref-type="table"}). In 2013, 69% of MS patients in Germany received DMDs, whereas in Poland, this only applied to 13%.^[@bibr4-1756286418759189]^ Moreover, the percentages of patients being treated with innovative drugs for (highly) active MS was considerably higher in countries such as Norway, Sweden and Denmark than in Slovenia, Poland, or Romania. [Table 2](#table2-1756286418759189){ref-type="table"} lists the current availability and reimbursement status of various DMDs in Austria, the Czech Republic, Hungary, Poland, Slovenia, and Slovakia. Any limitations and restrictions are described.

###### 

Determinants of access to multiple sclerosis treatment.

![](10.1177_1756286418759189-table1)

  -----------------------------------------------------------------------------------
  \+ Costs and the affordability of MS drugs\
  + Differences in the reimbursement process and patient eligibility for treatment\
  + Differences in diagnosis and clinical management of MS\
  + Regional differences inside the same country\
  + Use of patient registries or databases

  -----------------------------------------------------------------------------------

MS, multiple sclerosis.

###### 

Availability and reimbursement of disease-modifying drugs in the given indication as approved by the European Medicines Agency in central European multiple sclerosis Expert Board member countries.

\(a\) DMDs for mild/moderate RRMS.

![](10.1177_1756286418759189-table2)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                   Aubagio^®^                                    Avonex^®^                                     Betaferon^®^                                  Copaxone^®^                                   GLAT Gen                                      Extavia^®^                                    Plegridy^®^                                   Rebif^®^                                      Tecfidera^®^                                           Zinbryta^®^
  ---------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- ------------------------------------------------------ -------------------
  Austria          XX                                            XX                                            XX                                            XX                                            XX                                            Not available                                 XX                                            XX                                            XX                                                     Not reimbursed

  Czech Republic   XX\                                           XX\                                           XX\                                           XX\                                           XX\                                           XX\                                           XX\                                           XX\                                           XX\                                                    Not yet available
                   In RRMS with ⩾2 relapses in prior 12 months   In RRMS with ⩾2 relapses in prior 12 months   In RRMS with ⩾2 relapses in prior 12 months   In RRMS with ⩾2 relapses in prior 12 months   In RRMS with ⩾2 relapses in prior 12 months   In RRMS with ⩾2 relapses in prior 12 months   In RRMS with ⩾2 relapses in prior 12 months   In RRMS with ⩾2 relapses in prior 12 months   In active RRMS with ⩾1 relapse on prior DMD            

  Hungary          XX                                            XX                                            XX                                            XX                                            XX                                            XX                                            Not reimbursed                                XX                                            XX                                                     Not reimbursed

  Poland           XX                                            XX                                            XX                                            XX                                            XX\                                           XX                                            XX                                            XX                                            XX                                                     Not yet available
                                                                                                                                                                                                           For some MS centers                                                                                                                                                                                                                            

  Slovenia         XX                                            XX                                            XX                                            XX                                            XX                                            Not available                                 XX                                            XX                                            XX                                                     XX

  Slovakia         XX                                            XX                                            XX                                            XX                                            Not reimbursed                                XX                                            XX                                            XX                                            XX\                                                    Not yet available
                                                                                                                                                                                                                                                                                                                                                                                                   In moderate RRMS or in patients who failed prior DMD   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DMD, disease-modifying drug; gen, generic; RRMS, relapsing--remitting multiple sclerosis; XX, reimbursed and no limit of treatment duration.

###### 

\(b\) DMDs for (highly) active RRMS.

![](10.1177_1756286418759189-table3)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                   Gilenya^®^                                                                 Lemtrada^®^                                                                                Tysabri^®^
  ---------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------
  Austria          XX                                                                         Hospital-based drug, thus not reimbursed by sick funds                                     XX

  Czech Republic   XX                                                                         Not reimbursed                                                                             XX\
                                                                                                                                                                                         In active RRMS with ⩾2 moderate/severe relapses on prior DMD

  Hungary          XX                                                                         Named patient-based reimbursement by National Health Insurance, to be renewed every year   XX

  Poland           Reimbursed, but 60-month limit of treatment duration                       Reimbursed, but only for two courses of treatment                                          Reimbursed for:\
                                                                                                                                                                                         (1) Second line in JCV(−) RRMS patients\
                                                                                                                                                                                         (2) First line only in rapidly evolving severe RRMS with JCV(−), but 60-month limit of treatment duration

  Slovenia         XX                                                                         XX                                                                                         XX

  Slovakia         XX\                                                                        XX\                                                                                        XX\
                   In RRMS patients with high disease activity or who failed two prior DMDs   In RRMS patients with high disease activity or who failed two prior DMDs                   In RRMS patients with high disease activity or who failed three prior DMDs
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DMD, disease-modifying drug; JCV, John Cunningham virus; RRMS, relapsing--remitting multiple sclerosis; XX, reimbursed and no limit of treatment duration.

These differences are mainly a consequence of the DMD-related impact on health budgets against the backdrop of disparities in wealth across European countries. Lower-income countries usually pay lower prices for drugs. In Romania, Slovenia, Poland and the Czech Republic, prices have decreased between 2008 and 2013. However, according to the affordability index, Eastern countries are still less able to afford immunomodulatory agents, even though the index has improved as well. The improvement of the affordability index can partly be ascribed to increased expenses on health care in Eastern countries over time.

Most of the established treatments for mild/moderate relapsing MS have become available in Eastern European countries. However, certain reimbursement restrictions, such as limitations of the number of treated patients or limitations of duration of treatment, still occur. There is a correlation between the level of access and the healthcare infrastructure. For instance, Slovenia has a shortage of neurologists, which means that waiting times for neurological examinations for MS patients presently amount to almost 2 years. The availability of MS centers and MS nurses is also relevant in this context, as are differences in local treatment recommendations/guidelines.

Only 30--40% of patients respond well to first-line treatment, but drug escalation is a major hurdle in less well-heeled countries. Physicians actually tend to be hesitant about treatment escalation in general.

Regional variations can be much larger than differences between Western and Eastern countries. They include disparities in prescription behavior and referral of patients to more experienced hospitals. This is exemplified by the situation in Poland, where a substantial number of MS centers offers treatment for patients with mild-to-moderate relapsing disease, while drugs for highly active disease are prescribed only at a limited range of centers.

Another determinant of access is the use of registries or databases. A systematic survey has identified 20 European MS registries.^[@bibr5-1756286418759189]^ The collection of patient data in databases can help to optimize the management and advance knowledge about MS treatment in the local MS community. Cooperation and communication between MS centers is a crucial aspect here.

Several measures can improve patient access to treatment, such as the implementation of national strategies with the aim of reducing regional variation and devoting more resources to MS (e.g. increasing the numbers of neurologists and MS nurses). Decreases in costs of treatment are most likely to occur with the introduction of generics and biosimilars; however, governmental negotiations with the pharmaceutical companies also play a role here. Approval processes should be optimized, and administrative barriers should be removed. The collection of patient data through MS registries can contribute to enhanced access, as well as application of up-to-date national guidelines for treatment.

The upcoming European Committee for the Treatment and Research in Multiple Sclerosis--European Academy of Neurology clinical practice guideline {#section4-1756286418759189}
===============================================================================================================================================

For authorities and physicians alike, the availability of guidelines on the management of MS that can be perceived as a European consensus is essential. The first European clinical practice guidelines on pharmacological management of MS will be published this year by the European Academy of Neurology (EAN) and the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS). These guidelines strive to provide up-to-date, evidence-based recommendations on the treatment of adult patients with clinically isolated syndrome (CIS) or definite MS to guide healthcare professionals in the decision-making process.^[@bibr6-1756286418759189]^ Their focus is on DMDs, early treatment in CIS patients, treatment in patients with established disease, monitoring of treatment response as well as stopping or switching treatment. These guidelines do not prioritize any of the DMDs, as the available evidence does not inform such a recommendation. Not included are diagnostic guidelines, differential diagnostic guidelines, treatment of acute attacks, symptomatic treatment, and alternative treatments. The recommendations are not intended as a 'cookbook', but can be tailored to local requirements.

It was agreed that it is necessary to challenge the local governments to adhere to the European recommendations instead of finding medical explanations for adjustments that are actually economy driven. Importantly, the new guidelines might provide a basis for argumentation in negotiations with national authorities, thus facilitating improved reimbursement conditions or other amendments. For instance, CIS treatment is still not reimbursed in some European countries even though evidence unequivocally shows that it has beneficial effects.

The expert board cannot stress enough the need for education and specialization. Only qualified experts should treat patients with highly efficacious drugs due to the need for enhanced clinical vigilance and monitoring for treatment effects, including the risk of adverse events. Severe and significant adverse events such as natalizumab-related progressive multifocal leukoencephalopathy (PML) can be overlooked. Educational requirements also extend to neuroradiologists whose obligation it is to recognize the first signs of PML. On the part of the neurologist, clinical judgment can be pivotal here. The guidelines again emphasize that the physician's clinical vigilance and responsibility are at the center of patient management.

From a historical perspective, it is worth mentioning that the ECTRIMS--EAN guideline is not the first of its kind, as there has been international collaboration before. In 2008, the Multiple Sclerosis Therapy Consensus Group (MSTCG) issued therapeutic recommendations on basic and escalating immunomodulatory treatments.^[@bibr7-1756286418759189]^

Magnetic resonance imaging as an important interface {#section5-1756286418759189}
====================================================

MRI assessment, and thus the collaboration between neurologists and neuroradiologists, has been identified as an interface of growing importance in MS diagnosis and treatment. Issues in this context comprise the lack of standardized protocols for demyelinating disorders, as well as the absence of MS-specific qualification that is frequently observed in the (neuro)radiology community. For reasons of continuity, (neuro)radiologists should interpret a given patient's scans from diagnosis throughout follow up, and the same scanner should be used for each case. On the other hand, neurologists should be familiar with the basics of MRI to be able to communicate appropriately with their imaging partners. Close relationships between neurologists and radiologists are an asset that will facilitate collaboration.

It appears that considerable efforts are required to establish higher levels of quality with regard to the MRI interface. Expert interpretation is currently not available at every center, and consistency is lacking between centers. Rising numbers of scanners in the Eastern countries will increase the need for education of (neuro)radiologists on MS-related quality criteria in the years to come. We endorse the dissemination of the Magnetic Resonance Imaging in MS (MAGNIMS) protocol.^[@bibr8-1756286418759189],[@bibr9-1756286418759189]^ MAGNIMS guidelines need to be discussed and potentially adjusted for central European countries in a collaborative way. Expert MRI reading centers that offer secondary services in the daily routine are a potential solution, but this infrastructural approach must be handled with caution, as existing imaging partners need to be involved.

Contribution of multiple sclerosis registries {#section6-1756286418759189}
=============================================

There has been a growing emphasis on the collection and use of real-world data. In spite of several limitations (e.g. collection bias and interpretation bias), MS registries offer advantages such as assessment of drug escalation and medication switches/sequential treatments or the ascertainment of off-label use (e.g. in pediatric MS patients) of approved drugs. This information cannot be obtained by controlled clinical trials. A specific central European registry is currently not realistic, but many centers have started local, national or even international activities. Information on national and international MS registries established in Austria, the Czech Republic, Hungary, Poland, Slovenia, and Slovakia is summarized in [Table 3](#table4-1756286418759189){ref-type="table"}.

###### 

National and international multiple sclerosis registry participation in central European multiple sclerosis Expert Board member countries.

![](10.1177_1756286418759189-table4)

                   National registry                                                                                                          International registry
  ---------------- -------------------------------------------------------------------------------------------------------------------------- ------------------------------
  Austria          Independent national MS treatment registry since 2006, participation mandatory for MS centers                              No
  Czech Republic   Independent national MS registry (uses MSBase data collection tool)                                                        MSBase participation
  Hungary          No, but national MS treatment registry planned                                                                             MSBase participation
  Poland           National-Health-Fund-based MS treatment registry, participation mandatory for MS centers                                   No
  Slovenia         No, but national MS treatment registry planned                                                                             No
  Slovakia         Independent national MS registry since 2014, participation mandatory for neurologists (uses MSBase data collection tool)   MSBase participation planned

MS, multiple sclerosis; MSBase, international MS registry consortium.

Examples of successful registries are the MSBase Registry and the ReMus Czech National Registry. MSBase ([www.msbase.org](http://www.msbase.org)) includes over 40,000 patients worldwide.^[@bibr10-1756286418759189],[@bibr11-1756286418759189]^ More than 170 centers are participating in 32 countries. One of the reasons behind the success of this registry is the use of the user-friendly iMed (www.imed.org) tool. Also, centers remain the owners of their data. All of the investigators can request access to the dataset for analyses, and are entitled to start substudies. A substantial number of papers have been derived from the MSBase dataset to date.^[@bibr12-1756286418759189][@bibr13-1756286418759189][@bibr14-1756286418759189][@bibr15-1756286418759189][@bibr16-1756286418759189][@bibr17-1756286418759189][@bibr18-1756286418759189][@bibr19-1756286418759189][@bibr20-1756286418759189][@bibr21-1756286418759189][@bibr22-1756286418759189][@bibr23-1756286418759189][@bibr24-1756286418759189][@bibr25-1756286418759189][@bibr26-1756286418759189][@bibr27-1756286418759189][@bibr28-1756286418759189][@bibr29-1756286418759189][@bibr30-1756286418759189][@bibr31-1756286418759189][@bibr32-1756286418759189][@bibr33-1756286418759189][@bibr34-1756286418759189][@bibr35-1756286418759189][@bibr36-1756286418759189]--[@bibr37-1756286418759189]^

Likewise, the ReMus Czech National Registry ([www.nfimpuls.cz](http://www.nfimpuls.cz)), which was established in 2013, has already supplied various publications. The availability of data for negotiations with local authorities was one of the most important objectives for the setup of this registry. It is operated by the endowment fund Impuls, which is the owner of the data, in collaboration with the Czech neuroimmunological society. All of the 15 MS centers in the Czech Republic are contributing to the ReMus Registry. Again, the iMed software is being used to collect the data and report them twice yearly to the technical support organization. The findings are publicly available at the Impuls website ([www.multiplesclerosis.cz](http://www.multiplesclerosis.cz)). Data from almost 9000 patients treated with DMDs have been included up to this point, but enrollment of all MS patients in the Czech Republic is planned for the near future. Comparisons of the quality of care across different regions will become more important, as will assessment of factors such as employment status and time between disease onset and start of DMD treatment.

Finally, a national MS registry was also started in Slovakia in January 2016.

Multiple-sclerosis-related activities in Austria {#section7-1756286418759189}
================================================

The Austrian MS Treatment Registry as well as center-certification and educational processes serve as an example of integration that has continuously been increasing quality standards in the whole country. MS-related activities comprise the MS Treatment Registry, the MS Academy, MS center certification, MS center meetings and quality projects. There is a strong interaction between MS centers, MS societies, health authorities and pharmaceutical companies.

The Austrian MS Treatment Registry has been implemented as a treatment registry with the goals of achieving uniform quality standards of MS treatment documentation in Austria, transparent information for MS centers, alerts to missing control visits and for pharmacovigilance purposes, and conduct of scientific projects. A contract research organization (CRO) has been employed to guarantee maximum data quality by ensuring that the entries are plausible, complete and correct. CRO representatives respond to requests by neurologists at MS centers and contact them to promote high-value data collection. Due to these measures, enormous improvements have been observed over the past 2 years. As entering the data is time consuming for neurologists, a project aims to convince Austrian health insurances to provide specific remuneration for this type of documentation.

MS centers need to qualify for certification by fulfilling a set of requirements. They can be located both at hospitals and in the outpatient setting. Currently, there are 100 centers in Austria, but the majority of the Austrian MS patients are being treated at five large centers. Quality projects initiated by the MS network include the Austrian MS Library that was published in 2016. This is a manual containing evidence-based information on all aspects of MS for both patients and physicians.

Together, all of these projects have succeeded in convincing health authorities that the Austrian MS activities are helpful with regard to cost effectiveness. Recommendations have been increasingly accepted, and it is being acknowledged that the registry has led to a gradual gain in quality of care. Fruitful discussion between Austrian health authorities and MS specialists has been promoted on the strength of these efforts. Of course, it would be desirable to implement similar achievements on a large scale in European countries. Therefore, the next central European MS Expert Board meeting will focus exclusively on the harmonization of MS care in the countries represented.

Conclusion {#section8-1756286418759189}
==========

The participating central European countries have similarities in traditions of medical practice, which can be an opportunity to improve their standards of care of MS patients by learning from each other. On the other hand, there are substantial differences with regard to clinical management of MS, affordability of and access to drugs, and other factors. Pan-European data indicate a west--east gradient for the percentages of patients receiving DMD treatment in general and innovative second-line agents in particular. Insufficient numbers of available neurologists and specifically trained (neuro)radiologists appear to be in widespread shortage. Notably, achieving higher levels of quality is indispensable with respect to cooperation between neurologists and (neuro)radiologists, as MRI diagnostics are a cornerstone of MS management at the time of diagnosis and during follow up.

A common observation in all of the countries is the decline in quality of life with increasing EDSS scores, which is paralleled by steep increases in cost. This underscores the need to implement effective and timely treatment, also with a view to keeping patients in the workforce, which is a significant contributor to the cost-effectiveness of therapies. However, the interest of health authorities in these aspects is often amazingly limited due to the structure of funding systems in various countries that imply the provision of funds by different sources, which are seemingly unconnected. Authorities are encouraged to consider a more holistic view in the interest of patients and health care systems, and to acknowledge overall savings brought about by effective therapies in the long run. The upcoming ECTRIMS--EAN guidelines might contribute to facilitating negotiations with health authorities in the future, as well as pertinent data from MS treatment registries that have already been implemented in several of the participating countries. Existing examples show that combined activities with regard to education, documentation and patient care succeed in improving quality standards over time.
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